The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) today announced that given the current SARS-CoV-2 coronavirus evolution and the breadth in immune responses demonstrated by monovalent XBB.1.5 vaccines against circulating variants, the TAG-CO-VAC advises retaining the current COVID-19 vaccine antigen composition (monovalent XBB.1.5) as the COVID-19 vaccine antigen.
Read More
